Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Blood (2008) 112 (11): 91.

https://doi.org/10.1182/blood.V112.11.91.91

Published: 2008

Journal Articles

Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications.

Shaji Kumar, Lijun Zhang, Angela Dispenzieri, Scott Van Wier, Jerry Katzmann, Melissa Snyder, Emily Blood, Roberta DeGoey, Kim Henderson, Arthur Bradwell, Robert Kyle, Philip Greipp, S. Vincent Rajkumar, Rafael Fonseca

Blood (2008) 112 (11): 1677.

https://doi.org/10.1182/blood.V112.11.1677.1677

Published: 2008

Journal Articles

Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).

Susanna Jacobus, Shaji Kumar, Natalie Scott Callander, Rafat Abonour, Rafael Fonseca, David Siegel, Philip Greipp, S. Vincent Rajkumar

Blood (2008) 112 (11): 1740.

https://doi.org/10.1182/blood.V112.11.1740.1740

Published: 2008

Journal Articles

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

Wee J. Chng, MD, Marta Chesi, PhD, Tammy Price-Troska, Greg Ahmann, Kim Henderson, Philip Greipp, MD, Robert Kyle, MD, S. Vincent Rajkumar, MD, Morie Gertz, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD

Blood (2007) 110 (11): 241.

https://doi.org/10.1182/blood.V110.11.241.241

Published: 2007

Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD

Blood (2007) 110 (11): 74.

https://doi.org/10.1182/blood.V110.11.74.74

Published: 2007

Journal Articles

Progression risk for MGUS and SMM

Philip Greipp

Blood (2007) 110 (7): 2226.

https://doi.org/10.1182/blood-2007-07-097667

Published: 2007

Journal Articles

Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma.

Wee-Joo Chng, MD, Angela Baker, PhD, Travis Henry, PhD, Tammy Price-Troska, Scott Van Wier, Tae-Hoon Chung, PhD, Kim Henderson, Gregory Ahmann, Martha Lacy, MD, Angela Dispenzieri, MD, Morie Abraham Gertz, MD, Philip Greipp, MD, Peter Leif Bergsagel, MD, John Carpten, PhD, Rafael Fonseca, MD

Blood (2006) 108 (11): 113.

https://doi.org/10.1182/blood.V108.11.113.113

Published: 2006

Journal Articles

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

Blood (2006) 108 (11): 3407.

https://doi.org/10.1182/blood.V108.11.3407.3407

Published: 2006

Journal Articles

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Suzanne Hayman, MD, Morie Gertz, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Susan Geyer, PhD, Shaji Kumar, MD, Steven Zeldenrust, MD, Stephen Russell, MD, PhD, John Lust, MD, PhD, Robert Kyle, MD, Philip Greipp, MD, Thomas Witzig, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3568.

https://doi.org/10.1182/blood.V108.11.3568.3568

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison.

Shaji Kumar, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Nelson Leung, MD, Vincent Rajkumar, MD, Steven Zeldenrust, MD, John Lust, MD, Philip Greipp, MD, Dennis Gastineau, MD, Morie Gertz, MD

Blood (2006) 108 (11): 3091.

https://doi.org/10.1182/blood.V108.11.3091.3091

Published: 2006

Journal Articles

Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma.

Michael Timm, Linda Wellik, Teresa Kimlinger, Jessica Haug, Michael Kline, Ph.D, S. Vincent Rajkumar, MD, Philip Greipp, MD, Shaji Kumar, MD

Blood (2006) 108 (11): 3487.

https://doi.org/10.1182/blood.V108.11.3487.3487

Published: 2006

Journal Articles

Diagnostic Evaluation of t[4;14] in Multiple Myeloma.

Keith Stewart, Suzanne Trudel, Hong Chang, Kenneth C. Anderson, Paul Richardson, Melissa Alsina, Donna E. Reece, Philip Greipp, Steven Young, Alicia Sable-Hunt, ZhiHua Li, Jonathon Keats, Scott Van Wier, Gregory Ahmann, Tammy Price-Troska, Kathy Giusti, Rafael Fonseca

Blood (2006) 108 (11): 3501.

https://doi.org/10.1182/blood.V108.11.3501.3501

Published: 2006

Journal Articles

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Martha Lacy, MD, Morie Gertz, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Susan Geyer, PhD, Steven Zeldenrust, MD, Shaji Kumar, MD, Philip Greipp, MD, Rafael Fonseca, MD, John Lust, MD, Stephen Russell, MD, PhD, Robert Kyle, MD, Thomas Witzig, MD, Leif Bergsagel, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 798.

https://doi.org/10.1182/blood.V108.11.798.798

Published: 2006

Journal Articles

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, Philip Greipp, MD

Blood (2006) 108 (11): 799.

https://doi.org/10.1182/blood.V108.11.799.799

Published: 2006

Journal Articles

Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia.

Natalia C. Gonzalez-Paz, Scott Van Wier, Rafael Santana-Davila, Gregory Ahmann, Tammy Price-Troska, Kimberly Henderson, Morie Gertz, Robert Kyle, Philip Greipp, Rafael Fonseca

Blood (2005) 106 (11): 3267.

https://doi.org/10.1182/blood.V106.11.3267.3267

Published: 2005

Journal Articles

SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.

Brian G. Van Ness, John C. Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3488.

https://doi.org/10.1182/blood.V106.11.3488.3488

Published: 2005

Journal Articles

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Brian Van Ness, John Crowley, Emily Blood, Erik Rasmussen, Christine Ramos, Suzanne Grindle, Gareth Morgan, David Johnson, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3489.

https://doi.org/10.1182/blood.V106.11.3489.3489

Published: 2005

Journal Articles

Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.

Wee-Joo Chng, MD, Natalia Gonzalez-Paz, MD, Shaji Kumar, MD, Scott Van Wier, Gregory Ahmann, Tammy Price-Troska, Kim Henderson, Marta Chesi, PhD, Morie Gertz, MD, S. Vincent Rajkumar, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Robert Kyle, MD, Philip Greipp, MD, Rafael Fonseca, MD, Peter Leif Bergsagel, MD

Blood (2005) 106 (11): 3381.

https://doi.org/10.1182/blood.V106.11.3381.3381

Published: 2005

Journal Articles

Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes.

Wee-Joo Chng, MD, Scott Van Wier, Gregory Ahmann, Tammy Price-Troska, Kim Henderson, Marta Chesi, PhD, Morie Gertz, MD, S. Vincent Rajkumar, MD, Robert Kyle, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Philip Greipp, MD, Peter Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2005) 106 (11): 3006.

https://doi.org/10.1182/blood.V106.11.3006.3006

Published: 2005

Journal Articles

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Brian Van Ness, John Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Emily Blood, Antje Hoering, Bart Barlogie, Philip Greipp, Brian Durie

Blood (2005) 106 (11): 506.

https://doi.org/10.1182/blood.V106.11.506.506

Published: 2005

NARROW

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications.

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

Progression risk for MGUS and SMM

Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma.

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison.

Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma.

Diagnostic Evaluation of t[4;14] in Multiple Myeloma.

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia.

SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.

Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes.

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only